Free Trial

ANI Pharmaceuticals (ANIP) Competitors

ANI Pharmaceuticals logo
$94.79 +2.84 (+3.09%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$94.80 +0.01 (+0.01%)
As of 10/17/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANIP vs. ADMA, ANVS, MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, and NUVL

Should you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

ANI Pharmaceuticals vs. Its Competitors

ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

ADMA Biologics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

In the previous week, ANI Pharmaceuticals had 4 more articles in the media than ADMA Biologics. MarketBeat recorded 9 mentions for ANI Pharmaceuticals and 5 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.99 beat ANI Pharmaceuticals' score of 0.94 indicating that ADMA Biologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ADMA Biologics
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ANI Pharmaceuticals
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$426.45M8.04$197.67M$0.8616.70
ANI Pharmaceuticals$614.38M3.35-$18.52M-$0.77-123.10

ADMA Biologics presently has a consensus price target of $27.67, suggesting a potential upside of 92.66%. ANI Pharmaceuticals has a consensus price target of $99.14, suggesting a potential upside of 4.59%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
ANI Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 11.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ADMA Biologics has a net margin of 44.06% compared to ANI Pharmaceuticals' net margin of -1.37%. ADMA Biologics' return on equity of 41.01% beat ANI Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ADMA Biologics44.06% 41.01% 28.47%
ANI Pharmaceuticals -1.37%25.03%8.00%

Summary

ADMA Biologics beats ANI Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANIP vs. The Competition

MetricANI PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.06B$3.44B$6.21B$10.54B
Dividend YieldN/A2.28%5.70%4.80%
P/E Ratio-123.1023.1685.7027.13
Price / Sales3.35449.16581.70177.21
Price / Cash12.4846.9237.1060.81
Price / Book4.9610.4112.236.52
Net Income-$18.52M-$52.77M$3.33B$276.93M
7 Day Performance5.57%2.31%1.17%1.93%
1 Month Performance-2.07%12.59%6.85%2.19%
1 Year Performance57.17%11.18%58.93%34.62%

ANI Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANIP
ANI Pharmaceuticals
3.7706 of 5 stars
$94.79
+3.1%
$99.14
+4.6%
+57.2%$2.06B$614.38M-123.10600News Coverage
ADMA
ADMA Biologics
3.632 of 5 stars
$14.07
-4.0%
$27.67
+96.6%
-9.0%$3.50B$426.45M16.36530
ANVS
Annovis Bio
3.1586 of 5 stars
$2.25
+1.1%
$17.33
+672.1%
-78.4%$43.26MN/A-1.103
MRUS
Merus
1.3958 of 5 stars
$94.27
0.0%
$93.12
-1.2%
+80.1%$7.13B$56.23M-17.1437Short Interest ↓
RNA
Avidity Biosciences
2.5505 of 5 stars
$46.18
-1.7%
$68.32
+47.9%
-5.1%$6.86B$10.90M-12.97190News Coverage
Insider Trade
GRFS
Grifols
3.7489 of 5 stars
$9.61
-3.4%
$10.30
+7.2%
+11.6%$6.84B$7.81B8.2123,822
CYTK
Cytokinetics
3.8472 of 5 stars
$60.64
+6.4%
$76.64
+26.4%
+6.3%$6.82B$18.47M-11.89250Trending News
Insider Trade
RYTM
Rhythm Pharmaceuticals
2.8727 of 5 stars
$97.86
-1.2%
$106.64
+9.0%
+116.9%$6.58B$130.13M-32.51140News Coverage
Analyst Forecast
ABVX
Abivax
3.4891 of 5 stars
$86.67
+3.3%
$103.29
+19.2%
+787.4%$6.34BN/A0.0061Short Interest ↓
High Trading Volume
CRSP
CRISPR Therapeutics
2.2308 of 5 stars
$70.19
+3.6%
$71.50
+1.9%
+41.4%$6.16B$37.31M-12.93460Trending News
Analyst Forecast
Insider Trade
Analyst Revision
NUVL
Nuvalent
2.8471 of 5 stars
$83.85
-0.4%
$118.89
+41.8%
-10.8%$6.07BN/A-17.1140Trending News
Analyst Forecast
Insider Trade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:ANIP) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners